Eris Lifesciences Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 29 Jul 2026

Company page: Eris Lifesciences share price, financials & guidance record

Eris Lifesciences reported strong Q1 FY27 results with consolidated revenue up 13% and PAT up 14-15%, driven by a 14% growth in its Domestic Formulations Business. Key products like Insulin and Semaglutide performed well, and the Bhopal manufacturing unit is set to commercialize in August. However, the company faced underperformance in its OAD and Cardiac segments, a sequential decline in gross margins due to product mix, and slower-than-expected adoption for Semaglutide.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue down 23.3%, net profit down 52.0% against the same quarter last year.

₹ Cr · quarterly

Line item	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	400	405	579	650	315 −21%	277 −32%	444 −23%
Expenses	300	284	362	354	238	256	324
EBITDA	100	121	216	297	77 −23%	22 −82%	120 −44%
Margin	25%	30%	37%	46%	25%	8%	27%
Other income	8	17	23	24	10	27	26
Interest	55	53	45	46	45	43	42
Depreciation	47	43	38	39	39	39	40
Profit before tax	6	41	156	235	4 −33%	-33 −180%	64 −59%
Tax rate	70%	26%	36%	36%	21%	-74%	25%
Net profit	2	30	100	150	3 +50%	-9 −130%	48 −52%
EPS	0.13	2.24	7.34	10.98	0.23	-0.62	3.49

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls